Validation of assessments for preclinical AD registration

Validation of assessments for preclinical AD registration - Validation of assessments for preclinical AD registration

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030319

Enrollment

180

Registered

2017-12-08

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preclinical AD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Japanese native speakers 2) Living in community (not institutionalized) 3) Informed written consent 4) 60-90 years old

Exclusion criteria

Exclusion criteria: 1) dementia, Parkinson's disease, multiple cerebral infarction, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, epilepsia, subdural hematoma, multiple sclerosis, and head injury with after effect 2) detected infection or cerebral infarction by MRI 3) metallic substance in the body 4) major depression, bipolar disorder, alcohol or drug dependence, vitamin B12 deficiency, syphilis, and dysthyroidism 5) using psychoactive drug 6) having difficulty maintaining supine position 7) care-needs certification in the long-term care insurance system 8) HbA1c 6.5% or more

Design outcomes

Primary

Measure	Time frame
Amyloid accumulation using Positron Emission Tomography (PET)	—

Secondary

Measure	Time frame
Brain image: Magnetic Resonance Imaging (MRI) Cognitive function: Mini-Mental State Examination (MMSE), clinical dementia rating (CDR), National Center for Geriatrics and Gerontology-Functional Assessment Tool (NCGG-FAT): memory, attention, executive function, processing speed, working memory Blood sample: Single Nucleotide Polymorphism (SNP), DNA methylation, microRNA (miRNA), blood trace element Living situation: Medical condition, medication use, educational years, lifestyle, Activities of Daily Living (ADL), amount of conversation, quality of life (QOL), Geriatric Depression Scale (GDS)	—

Measure

Time frame

Brain image: Magnetic Resonance Imaging (MRI) Cognitive function: Mini-Mental State Examination (MMSE), clinical dementia rating (CDR), National Center for Geriatrics and Gerontology-Functional Assessment Tool (NCGG-FAT): memory, attention, executive function, processing speed, working memory Blood sample: Single Nucleotide Polymorphism (SNP), DNA methylation, microRNA (miRNA), blood trace element Living situation: Medical condition, medication use, educational years, lifestyle, Activities of Daily Living (ADL), amount of conversation, quality of life (QOL), Geriatric Depression Scale (GDS)

—

Countries

Japan

Contacts

Public ContactKeitaro Makino

National Center for Geriatrics and Gerontology Department of Preventive Gerontology

kmakino@ncgg.go.jp0562-45-5639

Outcome results